Once-monthly oral ibandronate (boniva) has favorable safety and tolerability in postmenopausal women with osteoporosis: 2-year results from MOBILE.

被引：0
|
作者：
Greenwald, M
Hawker, G
Cooper, C
Hughes, C
Mairon, N
Bonvoisin, B
Silverman, S
机构：
[1] Desert Med Adv, Palm Desert, CA USA
[2] Sunnybrook & Womens Coll Hosp, Toronto, ON, Canada
[3] Univ Southampton, MRC, Epidemiol Resource Ctr, Southampton SO9 5NH, Hants, England
[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[5] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [21] Once-monthly oral ibandronate effectively normalizes biochemical markers of bone resorption in postmenopausal osteoporosis: MOBILE 2-year analysis.
    Miller, PD
    Kendler, DL
    Garnero, P
    Silverman, S
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Christiansen, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S284 - S284
  • [22] Response to once-monthly and daily oral ibandronate in the mobile study: 2-year analysis
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S145 - S145
  • [23] Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: Results of BALTO II
    Hadji, P.
    Benhamou, C. -L.
    Devas, V.
    Masanauskaite, D.
    Barrett-Connor, E.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S69 - S69
  • [24] Once-monthly dosing of oral ibandronate is at least as effective as daily dosing in postmenopausal osteoporosis: 1-year results from mobile
    Reginster, JY
    Zikan, V
    Lorenc, R
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Stakkestad, JA
    BONE, 2005, 36 : S416 - S416
  • [25] Tolerability of monthly oral ibandronate in postmenopausal osteoporosis: 1-year results from the MOBILE study
    Recker, RR
    Silverman, SL
    Kendler, DL
    Dumont, E
    Hughes, BBC
    Reginster, JY
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S293 - S294
  • [26] Monthly oral ibandronate significantly reduces bone resorption in postmenopausal osteoporosis: 1-year results from MOBILE.
    Recker, RR
    Kendler, DL
    Adami, S
    Hughes, C
    Dumont, E
    Schimmer, RC
    Cooper, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S94 - S94
  • [27] Women prefer once-monthly oral ibandronate to weekly oral alendronate as postmenopausal osteoporosis treatment: Results of BALTO II
    Barrett-Connor, E.
    Bourgeois, P.
    Devas, V
    Masanauskaite, D.
    Minne, H.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S234 - S235
  • [28] Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis
    Lewiecki, E. Michael
    Keaveny, Tony M.
    Kopperdahl, David L.
    Genant, Harry K.
    Engelke, Klaus
    Fuerst, Thomas
    Kivitz, Alan
    Davies, Richard Y.
    Fitzpatrick, Lorraine A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (01): : 171 - 180
  • [29] Once-monthly oral ibandronate (150mg) provides superior efficacy versus daily dosing: 2-year results from mobile
    Felsenberg, D.
    Greenwald, M.
    Need, A.
    Elizondo-Alanis, L-J
    Hughes, C.
    Mairon, N.
    Coutant, K.
    Radominski, S.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S211 - S212
  • [30] Influence of baseline patient characteristics on response to once-monthly and daily oral ibandronate therapy: 2-year findings from mobile
    Reginster, J. Y.
    Hawker, G.
    Bolognese, M.
    Coutant, K.
    Hughes, C.
    Sedarati, F.
    Stone, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 426 - 426
12345